Patent · US Active

HCV fusion polypeptides

US8216590B2 · kind B2 · utility

2Cited by

6References

7Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Michael Houghton · Berkeley, US
Yin-Ling Lin · Emeryville, US
Angelica Medina-Selby · San Francisco, US
Doris Coit · Petaluma, US

Key dates

Filing date	Aug 27, 2007
Grant date	Jul 10, 2012
Priority date	—
Expiry date	Jun 15, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/24222
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.